13 Apr 2015
A retrospective study evaluating Valeritas, Inc’s lead product has found that patients who switched to V-Go experienced significant blood glucose improvement as well as a reduction in their total daily insulin. These findings support a positive impact on health care and pharmacy costs and could be applied more broadly at the health system and payer level.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024